Aerpio Kicking Off Phase IIb Studies for Promising First-in-Class Pipeline

Joseph Gardner, president and CEO, introduces the company’s first-in-class pipeline targeting the Tie2/VE-PTP pathway. Gardner delivers an extensive overview of Aerpio’s AKB-9778, a novel small molecule in Phase IIb for treatment of diabetic retinopathy. The company has a similar product – ARP-1536 – for DME.